About Me

I trained in medical sciences at Cambridge University and graduated with first-class honours in 1989…

About Me

Training

I trained in medical sciences at Cambridge University and graduated with first-class honours in 1989.  For my clinical medical training, I moved to Oxford University, qualifying as a doctor in 1992. After completing general medical training as a junior doctor, I trained in neurology at a number of London hospitals over a period of seven years, including the National Hospital for Neurology and Neurosurgery.  During this time, I developed my special interest and expertise in Parkinson’s and related disorders.  I did my PhD at University College, London in the genetics of movement disorders.

About my practice

I finished specialist training in 2004 and was appointed as a consultant neurologist at the Norfolk and Norwich University Hospital where I set up and developed a specialist Parkinson’s service.  In 2013 I moved to Cambridge and was appointed as a consultant neurologist at Addenbrooke’s Hospital where I have a general neurology practice diagnosing and treating headache, seizures, epilepsy, multiple sclerosis and stroke and functional neurological disorders.  I have continued to develop my special interest and expertise in Parkinson’s and movement disorders including dystonia, ataxia, and atypical parkinsonian disorders such as progressive supranuclear palsy, multiple systems atrophy and corticobasal degeneration.  

Training
I trained in medical sciences at Cambridge University and graduated with first-class honours in 1989.  For my clinical medical training, I moved to Oxford University, qualifying as a doctor in 1992. After completing general medical training as a junior doctor, I trained in neurology at a number of London hospitals over a period of seven years, including the National Hospital for Neurology and Neurosurgery.  During this time, I developed my special interest and expertise in Parkinson’s and related disorders.  I did my PhD at University College, London in the genetics of movement disorders.
 About my practice
I finished specialist training in 2004 and was appointed as a consultant neurologist at the Norfolk and Norwich University Hospital where I set up and developed a specialist Parkinson’s service.  In 2013 I moved to Cambridge and was appointed as a consultant neurologist at Addenbrooke’s Hospital where I have a general neurology practice diagnosing and treating headache, seizures, epilepsy, multiple sclerosis and stroke and functional neurological disorders.  I also work one day a week at the West Suffolk Hospital in Bury St Edmunds.  I have continued to develop my special interest and expertise in Parkinson’s and movement disorders including dystonia, ataxia, and atypical parkinsonian disorders such as progressive supranuclear palsy, multiple systems atrophy and corticobasal degeneration.  
 

Professional Profile Timeline

[[

1986 – Matriculated at Trinity College, Cambridge

[[

1988 – Elected senior scholar at Trinity College, Cambridge

[[

1989 – Graduated with First Class Honours from Trinity College, Cambridge

[[

1992 – Qualified as a doctor from University of Oxford Medical School

[[

1995 – Membership of the Royal College Of Physicians (MRCP)

[[

1995 – Began specialist training in neurology

[[

1997 – Started PhD at University College London

[[

2004 – Appointed consultant neurologist, Norfolk and Norwich University Hospital

[[

2006 – Elected Fellow, Royal College of Physicians of London

[[

2007 – Appointed to DeNDRoN Parkinson’s Clinical Studies Group

[[

2007 – One of the first UK neurologists to use Duodopa to treat Parkinson’s

[[

2007 – Appointed as DeNDRoN East Anglia Parkinson’s Specialty Lead

[[

2013 – Appointed consultant neurologist, Addenbrooke’s Hospital, Cambridge

[[

2014 – Elected to Council of Association of British Neurologists

[[

2014 – Elected as Honorary Secretary, Association of British Neurologists Movement Disorders Special Interest Group

[[

2014 – Appointed co-chair, Positive Steps in Parkinson’s annual conference

[[

2014 – Appointed as Specialty Lead for neurological research, UK Clinical Research Network (Eastern)

[[

2015 – Appointed Lead, Parkinson’s Excellence Network, Eastern

Professional Profile Timeline
[[
1986 – Matriculated at Trinity College, Cambridge
[[
1988 – Elected senior scholar at Trinity College, Cambridge
[[
1989 – Graduated with First Class Honours from Trinity College, Cambridge
[[
1992 – Qualified as a doctor from University of Oxford Medical School
[[
1995 – Membership of the Royal College Of Physicians (MRCP)
[[
1995 – Began specialist training in neurology
[[
1997 – Started PhD at University College London
[[
2004 – Appointed consultant neurologist, Norfolk and Norwich University Hospital
[[
2006 – Elected Fellow, Royal College of Physicians of London
[[
2007 – Appointed to DeNDRoN Parkinson’s Clinical Studies Group
[[
2007 – One of the first UK neurologists to use Duodopa to treat Parkinson’s
[[
2007 – Appointed as DeNDRoN East Anglia Parkinson’s Specialty Lead
[[
2013 – Appointed consultant neurologist, Addenbrooke’s Hospital, Cambridge
[[
2014 – Elected to Council of Association of British Neurologists
[[
2014 – Elected as Honorary Secretary, Association of British Neurologists Movement Disorders Special Interest Group
[[
2014 – Appointed co-chair, Positive Steps in Parkinson’s annual conference
[[
2014 – Appointed as Specialty Lead for neurological research, UK Clinical Research Network (Eastern)
[[
2015 – Appointed Lead, Parkinson’s Excellence Network, Eastern

Professional Memberships

Publications

Worth PF, Haining WN. (1990) Arabic, Persian & western medieval medicine. In: ‘A History of Medicine’ eds. Nancy Duin & Dr J. Sutcliffe. Morgan Samuel Editions.

Giunti P, David G, Worth PF, Stevanin G, Brice A, Wood NW (1999) Molecular and clinical study of 18 families with ADCA type II : evidence for genetic heterogeneity and de novo mutation. Am J Human Genet 64(6):1594-603

Worth PF, Giunti P, Gardner-Thorpe C, Dixon PH, Davis MB, Wood NW (1999) Autosomal Dominant Cerebellar Ataxia type III: Linkage of a large British family to a 7.6cM region on Chromosome 15q14-21.3. Am J Human Genet 65(2):420-6.

Worth PF, Houlden H, Giunti P, Davis MB, Wood NW (2000) Large expanded repeats in SCA8 are not confined to patients with cerebellar ataxia. Nat Genet 24(3):214-5

Worth PF, Wood NW. (2001) Genotype to Phenotype in the Spinocerebellar Ataxias. In: Malcolm S and Goodship J, editors. Genotype to Phenotype (2nd Ed). Oxford: BIOS Scientific Publishers: pp165-187

Worth PF, Brice A, Wood NW. (2001) Genotype-Phenotype correlation in the spinocerebellar ataxias. In: Harper PS and Perutz M, editors. Glutamine repeats and neurodegenerative diseases: molecular aspects. Oxford: Oxford University Press: pp221-236.

Sinha KK, Worth PF, Jha DK, Sinha S, Stinton VJ, Davis MB, Wood NW, Sweeney M, Bhatia KP (2003) Autosomal Dominant Cerebellar Ataxia (ADCA): SCA2 is the most frequent mutation in eastern India. J Neurol Neurosurg Psychiatry 75(3):448-52

Worth PF (2004) Sorting out Ataxia in Adults: a systematic approach to assessment and investigation. Practical Neurology  4(3):130-151

Worth PF, Stevens J, Lasri F, Brew S, Reilly MM, Rudge P, Mathias CJ. (2005) Syncope associated with pain as the presenting feature of neck malignancy: failure of cardiac pacemaker to prevent attacks in two cases. J Neurol Neurosurg Psychiatry 76(9):1301-3

Worth PF (2007) A perspective on the current issues in the diagnosis of Parkinson’s disease. Br J Hosp Med (Lond). 2007 May;68(5):S6, S8-11, S14-5.

Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P, Singleton AB, Hilton DA, Holton J, Revesz T, Davis MB, Giunti P, Wood NW. (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11.  Nat Genet. 12:1434-6

Vijayan S, Wilkinson M, Worth P. (2009) Conducting Research within the NHS: A Guide for Medical Students and a Closer Look into the Ethical Approval Process.  Reinvention: A Journal of Undergraduate Research. 2 (2)

Clarke CE, Worth P, Grosset D, Stewart D. (2009) Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease.  Parkinsonism Relat Disord 15(10):728-41

Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, Pfeil M, Myint PK (2011) The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials 12:251.

Giunti P, Houlden H, Gardner-Thorpe C, Worth PF, Johnson J, Hilton DA, Revesz T, Davis MB, Wood NW. (2012) Spinocerebellar ataxia type 11. Handb Clin Neurol. 103:521-34.

Worth P, Srinivasan V, Smith A, James I. Last JI, Wootton LL, Biggs PM, Davies NP, Carney EF, Byrd PJ, Taylor AMR. (2013) Very mild neurological phenotype in an adult with the classical cellular phenotype of ataxia telangiectasia. Mov Disord 28(4):524-8

Worth PF (2013) How to Treat Parkinson’s Disease in 2013 Clin Med. 13(1):93-6.

Worth PF. (2013) When the Going Gets Tough: How To Manage Patients with Advanced Parkinson’s Disease. Practical Neurology 13(3):140-52

Macphee GJ, Chaudhuri KR, David AS, Worth P, Wood B. (2013) Managing impulse control behaviours in Parkinson’s disease: practical guidelines.  Br J Hosp Med (Lond) 74(3):160-6.

Németh AH, Kwasniewska AC, Lise S, Parolin Schnekenberg R, Becker EB, Bera KD, Shanks ME, Gregory L, Buck D, Zameel Cader M, Talbot K, de Silva R, Fletcher N, Hastings R, Jayawant S, Morrison PJ, Worth P, Taylor M, Tolmie J, O’Regan M; UK Ataxia Consortium, Valentine R, Packham E, Evans J, Seller A, Ragoussis J. (2013) Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain 136(10):3106-18.

Daley DJ, Deane KH, Gray RJ, Clark AB, Pfeil M, Sabanathan K, Worth PF, Myint PK. (2014) Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomised controlled trial. Int J Clin Pract. 68(8):963-71.

PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.  Lancet 384(9949):1196-205.

Zis P, Martinez-Martin P, Sauerbier A, Rizos A, Sharma JC, Worth PF, Sophia R, Silverdale M, Chaudhuri KR (2015) Non-motor symptoms burden in treated and untreated early Parkinson’s disease patients: argument for non-motor subtypes. Eur J Neurol 22(8):1145-50.

Worth P. (2015) Results of the early stage PD MED study: revelation or recapitulation? Pract Neurol 15(6):408-10.

Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND. (2015) Tracking Parkinson’s: Study Design and Baseline Patient Data. J Parkinsons Dis. 2015;5(4):947-59.

Professional Memberships
Publications

Worth PF, Haining WN. (1990) Arabic, Persian & western medieval medicine. In: ‘A History of Medicine’ eds. Nancy Duin & Dr J. Sutcliffe. Morgan Samuel Editions.

Giunti P, David G, Worth PF, Stevanin G, Brice A, Wood NW (1999) Molecular and clinical study of 18 families with ADCA type II : evidence for genetic heterogeneity and de novo mutation. Am J Human Genet 64(6):1594-603

Worth PF, Giunti P, Gardner-Thorpe C, Dixon PH, Davis MB, Wood NW (1999) Autosomal Dominant Cerebellar Ataxia type III: Linkage of a large British family to a 7.6cM region on Chromosome 15q14-21.3. Am J Human Genet 65(2):420-6.

Worth PF, Houlden H, Giunti P, Davis MB, Wood NW (2000) Large expanded repeats in SCA8 are not confined to patients with cerebellar ataxia. Nat Genet 24(3):214-5

Worth PF, Wood NW. (2001) Genotype to Phenotype in the Spinocerebellar Ataxias. In: Malcolm S and Goodship J, editors. Genotype to Phenotype (2nd Ed). Oxford: BIOS Scientific Publishers: pp165-187

Worth PF, Brice A, Wood NW. (2001) Genotype-Phenotype correlation in the spinocerebellar ataxias. In: Harper PS and Perutz M, editors. Glutamine repeats and neurodegenerative diseases: molecular aspects. Oxford: Oxford University Press: pp221-236.

Sinha KK, Worth PF, Jha DK, Sinha S, Stinton VJ, Davis MB, Wood NW, Sweeney M, Bhatia KP (2003) Autosomal Dominant Cerebellar Ataxia (ADCA): SCA2 is the most frequent mutation in eastern India. J Neurol Neurosurg Psychiatry 75(3):448-52

Worth PF (2004) Sorting out Ataxia in Adults: a systematic approach to assessment and investigation. Practical Neurology  4(3):130-151

Worth PF, Stevens J, Lasri F, Brew S, Reilly MM, Rudge P, Mathias CJ. (2005) Syncope associated with pain as the presenting feature of neck malignancy: failure of cardiac pacemaker to prevent attacks in two cases. J Neurol Neurosurg Psychiatry 76(9):1301-3

Worth PF (2007) A perspective on the current issues in the diagnosis of Parkinson’s disease. Br J Hosp Med (Lond). 2007 May;68(5):S6, S8-11, S14-5.

Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, Worth P, Singleton AB, Hilton DA, Holton J, Revesz T, Davis MB, Giunti P, Wood NW. (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11.  Nat Genet. 12:1434-6

Vijayan S, Wilkinson M, Worth P. (2009) Conducting Research within the NHS: A Guide for Medical Students and a Closer Look into the Ethical Approval Process.  Reinvention: A Journal of Undergraduate Research. 2 (2)

Clarke CE, Worth P, Grosset D, Stewart D. (2009) Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease.  Parkinsonism Relat Disord 15(10):728-41

Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, Pfeil M, Myint PK (2011) The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials 12:251.

Giunti P, Houlden H, Gardner-Thorpe C, Worth PF, Johnson J, Hilton DA, Revesz T, Davis MB, Wood NW. (2012) Spinocerebellar ataxia type 11. Handb Clin Neurol. 103:521-34.

Worth P, Srinivasan V, Smith A, James I. Last JI, Wootton LL, Biggs PM, Davies NP, Carney EF, Byrd PJ, Taylor AMR. (2013) Very mild neurological phenotype in an adult with the classical cellular phenotype of ataxia telangiectasia. Mov Disord 28(4):524-8

Worth PF (2013) How to Treat Parkinson’s Disease in 2013 Clin Med. 13(1):93-6.

Worth PF. (2013) When the Going Gets Tough: How To Manage Patients with Advanced Parkinson’s Disease. Practical Neurology 13(3):140-52

Macphee GJ, Chaudhuri KR, David AS, Worth P, Wood B. (2013) Managing impulse control behaviours in Parkinson’s disease: practical guidelines.  Br J Hosp Med (Lond) 74(3):160-6.

Németh AH, Kwasniewska AC, Lise S, Parolin Schnekenberg R, Becker EB, Bera KD, Shanks ME, Gregory L, Buck D, Zameel Cader M, Talbot K, de Silva R, Fletcher N, Hastings R, Jayawant S, Morrison PJ, Worth P, Taylor M, Tolmie J, O’Regan M; UK Ataxia Consortium, Valentine R, Packham E, Evans J, Seller A, Ragoussis J. (2013) Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain 136(10):3106-18.

Daley DJ, Deane KH, Gray RJ, Clark AB, Pfeil M, Sabanathan K, Worth PF, Myint PK. (2014) Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomised controlled trial. Int J Clin Pract. 68(8):963-71.

PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.  Lancet 384(9949):1196-205.

Zis P, Martinez-Martin P, Sauerbier A, Rizos A, Sharma JC, Worth PF, Sophia R, Silverdale M, Chaudhuri KR (2015) Non-motor symptoms burden in treated and untreated early Parkinson’s disease patients: argument for non-motor subtypes. Eur J Neurol 22(8):1145-50.

Worth P. (2015) Results of the early stage PD MED study: revelation or recapitulation? Pract Neurol 15(6):408-10.

Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG; PRoBaND. (2015) Tracking Parkinson’s: Study Design and Baseline Patient Data. J Parkinsons Dis. 2015;5(4):947-59.

My Personal Time

Rowing.

I started rowing at City of Cambridge Rowing Club in 2014 when I moved to Cambridge. I now row and compete in the mens’ first or second boat

Car maintenance.

I own and maintain my late mother’s VW campervan which has been in our family since I was three years old.

Cooking.

I love to cook for family and friends

Family.

With five older sisters, and eight nephews and nieces, I like to spend time with my family.  I have two teenage daughters of whom I am very proud, one of whom is an aspiring elite rower, the other in the county netball squad.

Music.

I used to play the piano and sing quite well and am trying to relearn. Listening to and appreciating music of all kinds is central to my enjoyment and appreciation of life.

My Personal Time
Rowing.
I started rowing at City of Cambridge Rowing Club in 2014 when I moved to Cambridge. I now row and compete in the mens’ first or second boat
Car maintenance.
I own and maintain my late mother’s VW campervan which has been in our family since I was three years old.
Cooking.
I love to cook for family and friends
Family.
With five older sisters, and eight nephews and nieces, I like to spend time with my family.  I have two teenage daughters of whom I am very proud, one of whom is an aspiring elite rower, the other in the county netball squad.
Music.
I used to play the piano and sing quite well and am trying to relearn. Listening to and appreciating music of all kinds is central to my enjoyment and appreciation of life.